|
|
Article: Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA™ in Systemic Lupus Erythematosus.(Financial report)(Clinical report)
- Article from:
- Clinical Trials Week
- Article date:
- November 16, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Human Genome Sciences, Inc. (Nasdaq:HGSI) and GlaxoSmithKline PLC (GSK) announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care. Study results also showed that belimumab was generally well tolerated, as demonstrated by a similar rate of discontinuations due to adverse events across ...
Related newspaper, magazine, and journal articles:
|
|
Article: Human Genome Sciences Announces Closing of ...
PR Newswire;
August 3, 2009 ;
700+ words
... ... PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced the ... to buy any securities of Human Genome Sciences, Inc., nor shall there ... 800-831-9146. About Human Genome Sciences Human Genome Sciences is ...
|
|